Daiichi Sankyo Initiates Phase III Trial Of Its Investigational Factor Xa Inhibitor, DU-176b, In Patients With Atrial Fibrillation DAIICHI SANKYO Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trials for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by DAIICHI SANKYO.
Source: www.medicalnewstoday.comCan The US Learn From Dutch Universal Healthcare Coverage? The United States can learn from the Dutch
Health Insurance System model, according to an article by Pauline V. Rosenau, Ph.D., in the December issue of the/i Journal of
Health Politics, Policy and Law.
Source: www.medicalnewstoday.comRectal Malaria Drug Could Save Many Lives In Rural Africa And Asia A rectal application of the inexpensive antimalarial drug artesunate could save the lives of many people who develop severe malaria who live in the world's remotest locations, eg, rural Africa and Asia.
Source: www.medicalnewstoday.comResearchers Solve Piece Of Large-scale Gene Silencing Mystery - Opening The "X-files" Of Biology A team led by Craig Pikaard, Ph.D., Washington University in St. Louis professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
Source: www.medicalnewstoday.comSupposed Help Against Tumors - How Glioblastoma Tumor Cells Use The Body's Protection Glioblastoma is one of the most common but also most aggressive brain tumors, almost invariably leading to death in a short time. It consists of different cell types and their precursors, complicating successful treatment. To fight the driving force of the tumor - the tumor stem cells - scientists have been trying to initiate apoptosis in these cells. However, Dr.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
